Overview

FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer

Status:
Terminated
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety of a shorter course of radiation treatments combined with one year of androgen deprivation therapy. The study will test this treatment in men with high risk prostate cancer who have significant other illnesses or circumstances such that conventional long term radiotherapy and hormone therapy is not recommended by their physician or desired by the patient.
Phase:
Phase 2
Details
Lead Sponsor:
Lawson Health Research Institute
Treatments:
Androgens
Hormones
Prolactin Release-Inhibiting Factors